Comprehensive analysis of drug treatment options and prognostic assessment for fatty liver.

Drug Treatment:

Currently, there is no specific drug for treating fatty liver in clinical practice. Some drugs that lower blood lipids and protect and stabilize hepatocyte membranes have a certain therapeutic effect on fatty liver. For details on the application of lipid-lowering drugs, please refer to Section 1 of this chapter. Fenofibrate is commonly used in the treatment of fatty liver.

1. Fenofibrate The usual dose is 0.2g three times daily. Fenofibrate is a fibrate lipid-lowering drug that can reduce blood triglycerides and cholesterol, thereby reducing the accumulation of blood lipids in the liver and alleviating fatty liver.

2. Cholinergic Drugs The presence of lipid droplets in hepatocytes alters the ultrastructure of the cell membrane. Cells with altered ultrastructure do not receive sufficient energy for phospholipid synthesis, leading to reduced phospholipid synthesis. Phospholipids are essential components of cell membranes and subcellular membranes, playing a crucial role in cell regeneration. Choline is a precursor to phosphocholine and plays an important role in lipoprotein synthesis, increasing protein levels and promoting triglyceride excretion.

Commonly used medications include choline chloride, administered orally at a dose of 1g three times daily; or intravenously, compound choline at a dose of 2ml, once or twice daily.

3. Reduced glutathione (TN)
In chronic hepatic steatosis, the decrease in hepatic glutathione leads to a decline in the liver's detoxification function. Intravenous supplementation with reduced glutathione can significantly improve liver function indicators, such as transaminase levels.

4. Carnitine orotate (Liaoerjian)
Carnitine orotate complex is broken down in the body into carnitine and orotate, which are easily absorbed by hepatocytes. Orotate is a precursor to nucleic acid synthesis and an important substance that promotes the synthesis of proliferative proteins in damaged cells; while carnitine is a biological stimulant of lipid metabolism, promoting the β-oxidation of free fatty acids in the liver. Therefore, it can promote hepatocyte proliferation, restore liver enzymes, and improve symptoms.

5. Ursodeoxycholic acid (UDCA)
Usodeoxycholic acid is often used to treat chronic active hepatitis and intrahepatic cholestasis. Studies have shown that administration of UDCA 13-15 mg/(kg·d) for 12 months significantly reversed fatty liver disease and normalized abnormal liver function indicators.

6. Eicosapentaenoic acid (EPA)
EPA is often used as an anticoagulant and platelet aggregation inhibitor. Experimental studies have shown that EPA significantly reduces the degree of hepatic steatosis, possibly due to its ability to inhibit triglyceride synthesis in the liver and increase hepatic blood flow. In addition, EPA also inhibits the proliferation of fat cells and improves blood circulation, ensuring the delivery of nutrients to the brain.

7. Hepatoprotective drugs
Liver-protecting drugs have a stabilizing effect on hepatocyte membranes, which is beneficial for the recovery of damaged hepatocytes and can be taken long-term. Other drugs such as Hepatoprotective Agents are also used to treat fatty liver, but their efficacy requires further observation.

8. Rhubarb Extract Tablets
5-12 tablets per dose, 3 times daily. Take the medication 30 minutes before meals. It is advisable to have 3-4 bowel movements per day after taking the medication, and adjust the dosage accordingly.

9. Other Medications
Gynostemma pentaphyllum polyglycosides can lower blood lipids and are helpful for the recovery of fatty liver. Kudzu flower has a hangover-relieving effect. Kudzu flower extract can inhibit the increase of intrahepatic triglycerides caused by alcohol, etc., and has a certain effect on the treatment of alcoholic fatty liver.

Prognosis: The vast majority of fatty liver cases have a good prognosis. The disease progresses slowly, and removing the cause can leave no sequelae. Previously, it was believed that fatty liver rarely or almost never progressed to cirrhosis and liver failure. Recent studies have found that non-alcoholic fatty liver can develop into symptomatic cirrhosis and even liver failure. The mortality rate of fatty liver during pregnancy and Reye's syndrome is high.